Novo Nordisk about to receive important CHMP decision on Wegovy label extension
It is by no means insignificant when CHMP is expected to decide this week whether Novo Nordisk’s obesity drug Wegovy should be recognized for its ability to prevent serious cardiovascular diseases.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.